欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (4): 361-364.

• 综述与讲座 •    下一篇

表皮生长因子受体酪氨酸激酶抑制剂在肿瘤治疗中的应用

李哲, 袁守军   

  1. 军事医学科学院放射医学研究所药理室, 北京100850
  • 收稿日期:2003-11-26 修回日期:2003-12-18 出版日期:2004-04-26 发布日期:2020-11-20
  • 通讯作者: 袁守军, 男, 博士, 副研究员, 硕士生导师, 研究方向:肿瘤药理和药物安全评价。Tel:010-66930271 E-mail:yuansj@nic.bmi.ac.cn
  • 作者简介:李哲, 女, 理学硕士, 现工作单位为辽宁师范大学。

Application of epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy

LI Zhe, YUAN Shou-Jun   

  1. Department of Pharmacology, Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850,China
  • Received:2003-11-26 Revised:2003-12-18 Online:2004-04-26 Published:2020-11-20

摘要: 表皮生长因子受体(EGFR) 酪氨酸激酶, 是细胞外信号传递到细胞内的重要枢纽, 它在信号传导、细胞增殖、分化以及各种调节机制中发挥重要作用,在多种癌细胞中过度表达。许多研究表明, 抑制EGFR 酪氨酸激酶活性, 可抑制肿瘤生长。目前, 已有几种EGFR 酪氨酸激酶抑制剂进入了临床试验。本文对几种EGFR 酪氨酸激酶小分子抑制剂在肿瘤治疗中的研究进展做一综述。

关键词: 表皮生长因子受体, 酪氨酸激酶抑制剂, 肿瘤治疗, 临床试验

Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase is over-expressed in numerous human tumors, which plays pivotal roles in cellular signal transduction, and it is involved in a variety of tumor cellular behaviors such as proliferation, metastasis, angiogenesis and so on.Many investigations have indicated that tumor growth can be suppressed by inhibiting EGFR tyrosine kinase activity.Currently, several EGFR tyrosine kinase inhibitors are in clinical trial stage.

Key words: phacology, epidermal growth factor receptor (EGFR), tyrosine kinase inhibitors, cancer therapy, clinical trial

中图分类号: